Have a feature idea you'd love to see implemented?
Let us know!
ACLX Arcellx Inc
Price (delayed)
$87.22
Market cap
$4.72B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.71
Enterprise value
$4.62B
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which
Highlights
The equity has surged by 81% year-on-year
The EPS has surged by 73% year-on-year and by 32% since the previous quarter
Arcellx's quick ratio has soared by 52% YoY but it has decreased by 28% from the previous quarter
Key stats
What are the main financial stats of ACLX
Market
Valuations
Earnings
Shares outstanding
54.07M
Market cap
$4.72B
Enterprise value
$4.62B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.71
Price to sales (P/S)
30.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.65
Revenue
$155.82M
EBIT
-$37.24M
EBITDA
-$28.24M
Free cash flow
$3.58M
Per share
Balance sheet
Liquidity
EPS
-$0.71
Free cash flow per share
$0.07
Book value per share
$8.99
Revenue per share
$2.9
TBVPS
$14.21
Total assets
$764.91M
Total liabilities
$281.89M
Debt
$65.33M
Equity
$483.02M
Working capital
$450.28M
Debt to equity
0.14
Current ratio
4.29
Quick ratio
4.19
Net debt/EBITDA
3.42
Margins
Efficiency
Dividend
EBITDA margin
-18.1%
Gross margin
100%
Net margin
-25.9%
Operating margin
-44.6%
Return on assets
-5.2%
Return on equity
-8.3%
Return on invested capital
-6.9%
Return on capital employed
-5.9%
Return on sales
-23.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ACLX stock price
How has the Arcellx stock price performed over time
Intraday
0%
1 week
-8.27%
1 month
-3.39%
1 year
68.48%
YTD
57.15%
QTD
4.44%
Financial performance
How have Arcellx's revenue and profit performed over time
Revenue
$155.82M
Gross profit
$155.82M
Operating income
-$69.42M
Net income
-$40.42M
Gross margin
100%
Net margin
-25.9%
Arcellx's net margin has soared by 91% YoY and by 30% from the previous quarter
Arcellx's operating margin has soared by 85% YoY and by 20% from the previous quarter
Arcellx's net income has soared by 69% YoY and by 25% from the previous quarter
The company's operating income has surged by 52% YoY and by 14% QoQ
Growth
What is Arcellx's growth rate over time
Valuation
What is Arcellx stock price valuation
P/E
N/A
P/B
9.71
P/S
30.13
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
29.65
The EPS has surged by 73% year-on-year and by 32% since the previous quarter
The equity has surged by 81% year-on-year
ACLX's price to book (P/B) is 37% higher than its last 4 quarters average of 7.1
The price to sales (P/S) is 19% higher than the last 4 quarters average of 25.3
The company's revenue rose by 8% QoQ
Efficiency
How efficient is Arcellx business performance
The return on sales has surged by 91% year-on-year and by 31% since the previous quarter
The company's return on equity has surged by 83% YoY and by 33% QoQ
ACLX's return on invested capital has surged by 83% year-on-year and by 30% since the previous quarter
Arcellx's return on assets has surged by 78% YoY and by 29% QoQ
Dividends
What is ACLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ACLX.
Financial health
How did Arcellx financials performed over time
ACLX's total assets is 171% higher than its total liabilities
Arcellx's quick ratio has soared by 52% YoY but it has decreased by 28% from the previous quarter
Arcellx's current ratio has surged by 51% YoY but it has decreased by 29% QoQ
Arcellx's debt is 86% less than its equity
The equity has surged by 81% year-on-year
ACLX's debt to equity has dropped by 66% year-on-year and by 7% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.